Neurology and Clinical Neuroscience, published by WILEY, is a pivotal peer-reviewed journal dedicated to advancing knowledge in the fields of neurology and clinical neuroscience. With an ISSN of 2049-4173, it encompasses a diverse range of topics related to neurological disorders, offering a platform for groundbreaking research and clinical practices. Although the journal does not currently operate under an open access model, it aims to foster an inclusive academic environment by providing high-quality content that is accessible to both specialists and general practitioners in the medical community. Despite its relatively recent establishment from 2013 to 2024, the journal has gained recognition with Scopus rankings highlighting its role in clinical neurology and neuroscience spheres. It serves as an essential resource for researchers, professionals, and students seeking to expand their understanding and engage in current discussions surrounding neurological health and diseases.

Clinical Pharmacology in Drug Development, published by WILEY, is a distinguished journal dedicated to advancing the field of pharmaceutical science and drug development. With a strong commitment to disseminating cutting-edge research, this journal serves as a crucial platform for professionals, researchers, and students aiming to enhance their understanding of pharmacological principles and innovations in medical therapeutics. Since its inception in 2012, the journal has consistently maintained a noteworthy presence in the academic community, currently achieving a Q2 ranking in both Pharmaceutical Science and Medical Pharmacology categories as of 2023. Although the journal operates under a subscription model, it is highly regarded for its rigorous peer-reviewed publications, offering insights into drug efficacy, safety, and regulatory challenges. Positioned at the intersection of clinical practices and pharmaceutical advancements, Clinical Pharmacology in Drug Development plays an essential role in bridging the gap between scientific research and real-world application, ensuring that the latest therapeutic strategies are optimized for patient care.

VALUE IN HEALTH, published by Elsevier Science Inc, is a premier peer-reviewed journal in the fields of Health Policy, Medicine, and Public Health. With an impressive impact factor reflecting its respected standing, the journal has achieved a distinguished Q1 classification in multiple categories, placing it among the top publications in the health domain. Since its inception in 1998, this journal has been a vital platform for disseminating research that informs health policy and practice, impacting both clinical and public health decision-making. The journal’s Scopus rankings further underscore its global influence, with notable positions in Medicine and Public Health sectors. VALUE IN HEALTH is committed to fostering an environment where innovative research meets practical application, ultimately aiming to enhance health outcomes worldwide. Researchers, professionals, and students alike are encouraged to explore the wealth of knowledge contained within its pages.

Trials, published by BMC, is a leading open access journal that has been pioneering advancements in the field of medicine and pharmacology since its inception in 2006. With an impressive E-ISSN of 1745-6215, the journal is based in the United Kingdom and operates from its address at CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND. Trials is recognized for its impactful contributions to the research community, achieving a Q2 ranking in both the Medicine (miscellaneous) and Pharmacology (medical) categories according to the 2023 category quartiles. This esteemed journal aims to provide a platform for presenting cutting-edge clinical trials and methodological advances, effectively fostering collaboration and innovation among researchers, professionals, and students. The journal's accessibility, supported by its open access model, enhances the visibility and dissemination of vital research findings, ensuring that every contribution reaches a broad audience. As of 2024, Trials continues to be a crucial resource for anyone passionate about exploring new frontiers in medical research.

Contemporary Clinical Trials Communications, published by ELSEVIER INC, serves as a pivotal resource in the evolving fields of medicine and pharmacology, especially with its commitment to open access since 2015. With the E-ISSN 2451-8654, this journal is dedicated to disseminating high-quality research that examines contemporary clinical trial methodologies and their applications in improving healthcare outcomes. Situated in the United States, its impressive ranking, with a Q2 status in both Medicine (miscellaneous) and Pharmacology for 2023, highlights its significance and impact within the scientific community. Ranking #199 out of 636 in General Medicine and #217 out of 313 in Pharmacology on the Scopus scale, the journal aims to foster innovative discussions and developments among researchers, professionals, and students, making it an essential tool for those seeking to stay at the forefront of clinical research and trials.

The JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, published by SAGE PUBLICATIONS INC, is a premier resource in the fields of cardiology and pharmacology, with an impressive impact factor reflective of its significant contributions to the scientific community. Established in 1996 and continuing through 2024, this journal is indexed in Scopus, achieving notable rankings, including Q2 in both Cardiology and Cardiovascular Medicine and Pharmacology. By fostering a multidisciplinary approach, it aims to improve pharmaceutical therapies and patient outcomes in cardiovascular health. Although not an open-access journal, it provides various subscription options to grant access to its cutting-edge research and reviews. As a vital platform for meaningful discourse and innovation in cardiovascular pharmacology, the journal attracts a diverse readership of researchers, professionals, and students, enhancing knowledge and advancing the field.

Journal of Biopharmaceutical Statistics, published by Taylor & Francis Inc, is a premier scholarly journal that has been contributing to the fields of biostatistics and pharmacology since its inception in 1991. With an impressive track record spanning over three decades, it holds a significant place in the academic landscape, particularly evidenced by its Q2 quartile rankings in Pharmacology, Pharmacology (Medical), and Statistics and Probability as of 2023. The journal serves as a vital platform for researchers, professionals, and students, disseminating critical statistical methodologies and innovative analyses that enhance drug development and biopharmaceutical research. Although not open access, it provides invaluable insights through meticulously peer-reviewed articles that tackle pressing issues in pharmacometric modeling, clinical trial design, and statistical theory. As the biopharmaceutical industry evolves, Journal of Biopharmaceutical Statistics remains pivotal in fostering scientific discovery and excellence.

Statistics in Biopharmaceutical Research, published by Taylor & Francis Inc, is a premier journal that occupies a crucial space in the realms of Pharmaceutical Science and Statistics and Probability. With a robust impact factor affirmed by its Q1 rankings in both categories, the journal stands as a beacon for innovative statistical methodologies and their applications in biopharmaceutical research. Researchers and professionals will find a rich repository of high-quality articles that address contemporary challenges in drug development, clinical trials, and regulatory frameworks. Since its inception in 2011, the journal has continued to foster interdisciplinary collaboration, making significant strides towards enhancing statistical practice in biomedicine. With a commitment to academic rigor and practical relevance, Statistics in Biopharmaceutical Research is an essential resource for anyone looking to advance their understanding and application of statistical techniques in the pharmaceutical industry.

Future Oncology is a premier peer-reviewed journal published by FUTURE MEDICINE LTD, dedicated to advancing research and innovation within the field of oncology. Established in 2005 and set to continue through 2024, this journal serves as an essential resource for researchers, healthcare professionals, and students engaged in cancer studies. With its emphasis on groundbreaking findings and multidisciplinary approaches, Future Oncology holds an esteemed reputation, reflected in its 2023 category quartiles ranking it in Q2 for Cancer Research and Q1 for Medicine (miscellaneous). The journal is indexed in Scopus, showcasing its rigorous content, with rankings in the 63rd percentile for Oncology and the 46th percentile for Cancer Research. Although it does not operate on an open-access model, its commitment to disseminating cutting-edge findings makes it an invaluable asset for those seeking to stay at the forefront of oncology research.Future Oncology strives to bridge the gap between laboratory and clinical research, fostering collaboration and appreciation for the complexities of cancer treatment.

Therapeutic Innovation & Regulatory Science, published by Springer Heidelberg, is an esteemed journal that focuses on the intersection of therapeutic innovations and the regulatory frameworks that govern them. Established in 1970 and continuing its legacy of excellence through converged years, this journal plays a crucial role in supplying cutting-edge research, reviews, and discussions that advance understanding in the fields of pharmacology and healthcare regulation. With an impact factor reflective of its rigorous peer-review standards, this journal holds a prestigious Q1 ranking in Pharmacology, Toxicology, and Pharmaceutics (Miscellaneous) for 2023, reflecting its influence and the high quality of its published material. The journal's wide scope also embraces public health and environmental studies, making it an essential resource for researchers and professionals navigating these critical areas. Open access options enhance its visibility and accessibility, ensuring that the latest discoveries and regulatory insights are readily available to a global audience. For those at the forefront of medicinal science and regulatory affairs, Therapeutic Innovation & Regulatory Science is your avenue to understanding pivotal innovations that shape contemporary therapeutic practices.